Chemomab CFO files initial insider holdings
Chemomab Therapeutics Ltd. Chief Financial Officer Fatal Sigal filed an initial ownership report showing current holdings in American Depositary Shares (ADSs), stock options, and restricted share units.
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. Chief Financial Officer Fatal Sigal filed an initial ownership report showing current holdings in American Depositary Shares (ADSs), stock options, and restricted share units. The filing lists three option grants over ADSs with exercise prices of $39.31, $8.44, and $6.80 per ADS, expiring between November 2031 and June 2033, along with multiple ADS and RSU positions that vest in stages through 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Fatal Sigal
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy American Depositary Shares) — 41,965 contracts (Direct);
American Depositary Shares — 37,450 shares (Direct)
Footnotes (5)
- F1. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.
- F2. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.
- F3. The options reported in this row were granted to the Reporting Person by the Issuer on November 11, 2021, and are fully vested and exercisable as of the date of this report.
- F4. The options reported in this row were granted to the Reporting Person by the Issuer on November 8, 2022, and vest and become exercisable according to following schedule: 25% on November 8, 2023, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on November 8, 2026.
- F5. The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 14, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 15, 2027.
Key Figures
Option exercise price: $39.31 per ADS
Option exercise price: $8.44 per ADS
Option exercise price: $6.80 per ADS
+5 more
8 metrics
Option exercise price
$39.31 per ADS
Stock option over American Depositary Shares expiring November 11, 2031
Option exercise price
$8.44 per ADS
Stock option over American Depositary Shares expiring November 8, 2032
Option exercise price
$6.80 per ADS
Stock option over American Depositary Shares expiring June 14, 2033
Underlying option shares
8,900 ADSs
Underlying American Depositary Shares for $39.31 options
Underlying option shares
7,350 ADSs
Underlying American Depositary Shares for $8.44 options
Underlying option shares
25,715 ADSs
Underlying American Depositary Shares for $6.80 options
Direct ADS holding example
9,728 ADSs
American Depositary Shares shown as held directly
RSU full vesting date
October 1, 2028
RSUs granted October 1, 2024 fully exercisable by this date
Key Terms
American Depositary Shares, restricted share units ("RSUs"), stock option, vest and become exercisable, +1 more
5 terms
stock option financial
"Stock option (right to buy American Depositary Shares)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest and become exercisable financial
"vest and become exercisable according to following schedule: 25% on October 1, 2025"
quarterly installments of 6.25% financial
"thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Chemomab (CMMB) Form 3 filing by Fatal Sigal show?
The Form 3 shows Fatal Sigal’s initial holdings in Chemomab securities as Chief Financial Officer, including American Depositary Shares, stock options, and restricted share units. It details option exercise prices, expiration dates, and RSU vesting schedules that extend through 2029, without reporting any new trades.
How many Chemomab (CMMB) ADSs are covered by Fatal Sigal’s stock options?
The filing lists stock options over 8,900, 7,350, and 25,715 American Depositary Shares. These options have exercise prices of $39.31, $8.44, and $6.80 per ADS and expire between November 2031 and June 2033, reflecting existing equity-based compensation arrangements.
What are the exercise prices and expirations of Fatal Sigal’s Chemomab stock options?
Sigal holds options with exercise prices of $39.31, $8.44, and $6.80 per American Depositary Share. According to the filing, these options expire on November 11, 2031, November 8, 2032, and June 14, 2033, respectively, and represent long-dated equity incentives.
What RSU vesting schedules are disclosed for Chemomab (CMMB) CFO Fatal Sigal?
The filing describes RSUs granted on October 1, 2024 and April 10, 2025. Each grant vests 25% on the one-year anniversary, then in 12 equal quarterly installments of 6.25%, so the October 2024 RSUs fully vest by October 1, 2028 and the April 2025 RSUs by April 10, 2029.
Does the Chemomab (CMMB) Form 3 indicate any recent insider buying or selling?
The Form 3 is an initial ownership statement and lists holdings and award terms rather than new transactions. All entries are categorized as holdings with unknown transaction codes, so it does not indicate recent open-market purchases or sales by Fatal Sigal.
What direct ADS holdings does Fatal Sigal report in Chemomab (CMMB)?
The filing lists several direct positions in American Depositary Shares, including rows showing 9,728, 15,222, and 12,500 ADSs following the reported holdings. Some of these ADS positions are tied to RSU grants that vest over multiple years according to the disclosed schedules.
AI-generated analysis. How Rhea-AI works. Not financial advice.
